Bluher M, Rosenstock J, Hoefler J, Manuel R, et al. Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. Diabetologia 2023 Dec 14. doi: 10.1007/s00125-023-06053.
PMID: 38095657